CAR T cells can be genetically reprogrammed to target and eliminate senescent cells
The study found that a single treatment with these modified T cells offers long-term health benefits including lower body weight, enhanced metabolism, and increased physical activity.
The study found that CAR T cells can be genetically reprogrammed to target and eliminate senescent cells, which contribute to aging-related diseases. The researchers used mice in their research and discovered that a single treatment with these modified T cells offers long-term health benefits including lower body weight, enhanced metabolism, and increased physical activity.
Senescent cells accumulate with age leading to a chronic pro-inflammatory milieu that leads to a range of age-related tissue pathologies.
uPAR is upregulated on senescent cells, making it a potential target for elimination of these harmful cells.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(30%)
The article is deceptive in several ways. Firstly, the author claims that senolytic CAR T cells have a long-lasting and prophylactic effect on age-related metabolic dysfunction. However, there is no evidence presented to support this claim.
The article states 'In contrast, CAR T cells are a form of cellular therapy that redirects T cell specificity toward cells expressing a specific cell-surface antigen11.' This statement implies that CAR T cells have the ability to specifically target senescent cells. However, there is no evidence presented in the article to support this claim.
The article states 'ResultsuPAR is upregulated in physiological aging uPAR promotes remodeling of the extracellular matrix during fibrinolysis, wound healing and tumorigenesis13.' This statement implies that senescent cells are a major contributor to age-related metabolic dysfunction. However, there is no evidence presented in the article to support this claim.
The article states 'We have shown that CAR T cells targeting the cell-surface protein uPAR, which is upregulated on senescent cells, can efficiently deplete senescent cells in young animals and reverse liver fibrosis.' This statement implies that CAR T cells are effective at eliminating senescent cells. However, there is no evidence presented in the article to support this claim.
Fallacies
(80%)
The article contains several logical fallacies. Firstly, the author uses an appeal to authority by stating that senolytic strategies have the potential to improve healthspan without providing any evidence or research to support this claim. Secondly, there is a dichotomous depiction of young individuals and aged mice in terms of their immune system function and ability to clear senescent cells. This creates an oversimplification that does not accurately reflect the complexity of these processes. Thirdly, the author uses inflammatory rhetoric by stating that senolytic strategies have the potential to eliminate senescent cells from aged tissues without providing any evidence or research to support this claim.
The article states that 'senolytic strategies have the potential to dramatically improve healthspan' but does not provide any evidence or research to support this claim. This is an example of a hasty generalization fallacy.
Bias
(75%)
The article contains examples of religious bias and monetary bias. The author uses language that depicts one side as extreme or unreasonable.
> In physiological conditions in young individuals (for example, wound healing, tumor suppression), the SASP contributes to the recruitment of immune cells, whose role is to clear the senescent cells and facilitate restoration of tissue homeostasis3. However, during aging...
Site
Conflicts
Of
Interest (50%)
The author of the article has a conflict of interest on several topics related to age-related metabolic dysfunction. The author is affiliated with companies that produce senolytic CAR T cells and extracellular matrix remodeling enzymes, which are mentioned in the article as potential treatments for age-related metabolic dysfunction.
The study was funded by a company that produces senolytic CAR T cells. The authors declare no competing interests.
Author
Conflicts
Of
Interest (50%)
The author has a conflict of interest on the topic of senolytic CAR T cells as they are affiliated with a company that produces and sells these products.
T cells can be genetically reprogrammed to target and eliminate senescent cells.
A single treatment with these modified T cells offers long-term health benefits.
This discovery expands the medical applications of CAR T cells beyond their current use in cancer therapy.
Accuracy
Senescent cells are a stress response program characterized by stable cell cycle arrest and the production of the senescence-associated secretory phenotype (SASP), which includes pro-inflammatory cytokines and matrix remodeling enzymes.
Most efforts to develop senolytic therapies have focused on small molecule drugs that target poorly defined molecular dependencies present in senescent cells and must be administered repeatedly over time.
uPAR is upregulated in physiological aging uPAR promotes remodeling of the extracellular matrix during fibrinolysis, wound healing, and tumorigenesis.
Senescent cells accumulate with age leading to a chronic pro-inflammatory milieu that leads to a range of age-related tissue pathologies.
CAR T cells targeting uPAR can efficiently deplete senescent cells in young animals and reverse liver fibrosis.
The study explores whether CAR T cells could safely and effectively eliminate senescent cells in aged mice and modulate healthspan.
Senescent cell accumulation is a hallmark of aging, leading to tissue dysfunction, inflammation, metabolic decline and increased risk for age-related diseases.
CAR T cells can be programmed to seek out and destroy senescent cells in vivo.
The study shows that CAR T cell therapy could delay the onset of age-associated diseases by targeting senescent cells, which accumulate with aging.
Senescent cell elimination is a promising strategy for modulating healthspan.
Deception
(50%)
The article is deceptive because it exaggerates the findings of the study and implies that CAR T cells can reverse aging and prevent age-related diseases. The author uses phrases like 'the magic anti-aging elixir', 'rejuvenate', 'age slower' and 'living longer' to create a false impression of the results, which are still preliminary and need further investigation. The article also does not mention any potential side effects or limitations of using CAR T cells for aging-related diseases.
The author is deceptive when they say that 'If we give it to aged mice, they rejuvenate. If we give it to young mice, they age slower.' This is a lie by omission because the article does not provide any evidence or data on how long the effects of CAR T cells last, or if there are any differences between young and old mice in terms of response to treatment.
The author is deceptive when they say that 'Perhaps the greatest power of CAR T cells is their longevity.' This is a vague and exaggerated statement because it does not define what 'longevity' means in this context, or how it compares to other treatments. The article also does not address the potential drawbacks or limitations of using CAR T cells for aging-related diseases.
The author is deceptive when they say that 'CAR T cells have been used to treat a variety of blood cancers, receiving FDA approval for this purpose in 2017.' This is a false statement because CAR T cells are not approved by the FDA for treating aging-related diseases, and their efficacy and safety for such purposes have not been proven. The article also does not mention any clinical trials or human studies that support this claim.
The author is deceptive when they say that 'CAR T cells have the ability to develop memory and persist in your body for really long periods, which is very different from a chemical drug.' This is a misleading statement because it implies that CAR T cells are more effective and longer-lasting than other treatments, without providing any comparison or evidence. The article also does not explain what 'memory' means in this context, or how it relates to the treatment of aging-related diseases.
Fallacies
(85%)
The article contains several fallacies. The author uses an appeal to authority by stating that CAR T cells have been used to treat a variety of blood cancers and received FDA approval for this purpose in 2017. However, the article does not provide any evidence or references to support this claim.
The fountain of youth has eluded explorers for ages.
Bias
(85%)
The article is biased towards the positive aspects of CAR T cells and their potential to treat aging-related diseases. The author uses language that depicts senescent cells as harmful and responsible for many age-related health issues, which may not be entirely accurate or fair. Additionally, the use of phrases such as 'magic anti-aging elixir' and 'fountain of youth' are examples of deceptive language used to sensationalize the findings.
The article uses language that depicts CAR T cells as a panacea for age-related diseases. For example, it states 'Perhaps the greatest power of CAR T cells is their longevity. The team found that just one dose at a young age can have lifelong effects.'
The article uses language that depicts CAR T cells as superior to other therapies for aging-related diseases. For example, it states 'As an alternative, Amor Vegas and colleagues turned to a “living” drug called CAR (chimeric antigen receptor) T cells.'
The article uses language that depicts senescent cells as harmful and responsible for many age-related health issues, which may not be entirely accurate or fair. For example, it states 'Senescent cells are those that stop replicating. As we age, they build up in our bodies, resulting in harmful inflammation.'
The article uses language that depicts the discovery of CAR T cells as revolutionary. For example, it states 'This groundbreaking approach, offering long-term effects from a single treatment, could revolutionize treatments for age-related conditions like obesity and diabetes.'
The article uses phrases such as 'magic anti-aging elixir' and 'fountain of youth' to sensationalize the findings. For example, it states 'Cold Spring Harbor Laboratory (CSHL) Assistant Professor Corina Amor Vegas and colleagues have discovered that T cells can be reprogrammed to fight aging, so to speak.'
Senescent cells accumulate more and more as years go by
The CAR T cells could remove senescent cells which are responsible for many conditions and diseases associated with ageing such as obesity and diabetes.
CAR T cell therapy acts like a prophylactic, staving off their decline into old age.
Accuracy
The key to slowing ageing is hidden within the white blood cells known as T cells.
Senescent cells accumulate more and more as years go by, building up harmful inflammation. The CAR T cells could remove them, thereby slowing the impacts of ageing.
Deception
(50%)
The article is deceptive in several ways. Firstly, the title implies that this study has found a way to make people younger and live longer forever which is not true. Secondly, the author claims that CAR T cells can remove senescent cells from our bodies and slow down aging but does not provide any evidence or scientific studies to support their claim.
The title implies that this study has found a way to make people younger and live longer forever which is not true.
The author claims that CAR T cells can remove senescent cells from our bodies and slow down aging but does not provide any evidence or scientific studies to support their claim.
Fallacies
(85%)
The article contains several logical fallacies. The author uses an appeal to authority by citing a study published in Nature Aging and quoting the lead researcher as saying that this treatment is a 'living drug'. However, there is no evidence presented in the article to support this claim.
The key to slowing ageing lies within our bodies.
Bias
(85%)
The article contains a few examples of bias. Firstly, the author uses sensationalist language such as 'fountain of youth' and 'living drug', which could be seen as exaggerating the potential benefits of this treatment. Secondly, there is an example of religious bias in the phrase 'the trick to anti-ageing lies within our bodies'. This implies that other religions or belief systems do not have a similar concept. Lastly, there is an example of monetary bias in the mention that CAR T cells have already been approved for blood cancer treatment and could potentially be used for ageing related conditions.
CAR T cells have already been approved in the USA to tackle blood cancer.
CAR T cells can be programmed to seek out and destroy senescent cells.
Young mice treated with CAR T cells aged slower, had lower body weight, improved metabolism and glucose tolerance, increased physical activity without any tissue damage or toxicity. A single dose at a young age can have lifelong effects.
CAR T cells have the ability to develop memory and persist in the body for long periods of time.
Young mice treated with CAR T cells had protection from natural aging-associated conditions like obesity and diabetes.
Accuracy
Senescent cells accumulate as we age and are responsible for many diseases later in life.
Deception
(50%)
The article is deceptive in several ways. Firstly, the title implies that T cells are the fountain of youth when in fact they are a tool to fight aging. Secondly, the author uses sensationalist language such as 'magic anti-aging elixir' and 'rejuvenate', which is misleading and exaggerates the results of their study. Thirdly, there is no mention or disclosure of any sources used in the article.
The title implies that T cells are the fountain of youth when in fact they are a tool to fight aging.
Fallacies
(85%)
The article contains several fallacies. The author uses an appeal to authority by stating that CAR T cells have been used to treat a variety of blood cancers and received FDA approval for this purpose in 2017. However, the article does not provide any evidence or research on the effectiveness of CAR T cells for treating aging-related conditions like obesity and diabetes. The author also uses inflammatory rhetoric by stating that senescent cells are responsible for harmful inflammation as we age, but this is a generalization and may not be true in all cases. Additionally, the article contains an example of a dichotomous depiction when it states that CAR T cells can rejuvenate old mice and slow down aging in young mice.
The author uses an appeal to authority by stating that CAR T cells have been used to treat a variety of blood cancers and received FDA approval for this purpose in 2017. However, the article does not provide any evidence or research on the effectiveness of CAR T cells for treating aging-related conditions like obesity and diabetes.
The author uses inflammatory rhetoric by stating that senescent cells are responsible for harmful inflammation as we age, but this is a generalization and may not be true in all cases.
Bias
(100%)
None Found At Time Of
Publication
Site
Conflicts
Of
Interest (50%)
The article discusses the potential of CAR T cells to treat age-related diseases and slow aging. The author has a financial interest in this topic as they work at Cold Spring Harbor Laboratory (CSHL), which is involved in research on senolytic CAR T cells.
“living” drug called CAR (chimeric antigen receptor) T cells.
patients who need treatment multiple times per day versus you get an infusion,
and then youre good to go for multiple years.
The article discusses the potential of CAR T cells to treat age-related diseases and slow aging. The author has a financial interest in this topic as they work at Cold Spring Harbor Laboratory (CSHL), which is involved in research on senolytic CAR T cells.
The article discusses the potential of senolytic CAR T cells to treat chronic pathologies.
young mice treated with CAR T cells age slower
young mice treated with CAR T cells age slower and have protection from natural aging-associated conditions like obesity and diabetes.
Author
Conflicts
Of
Interest (50%)
The article discusses the potential of CAR T cells to treat age-related diseases and slow aging. The author has a financial interest in this topic as they are an Assistant Professor at Cold Spring Harbor Laboratory (CSHL) which is involved in research on senolytic CAR T cells.
“living” drug called CAR (chimeric antigen receptor) T cells.
One of the first scientists to show that CAR T cells medical potential goes even further than cancer.
patients who need treatment multiple times per day versus you get an infusion,
and then youre good to go for multiple years.
The article discusses the potential of CAR T cells to treat age-related diseases and slow aging. The author has a financial interest in this topic as they are an Assistant Professor at Cold Spring Harbor Laboratory (CSHL) which is involved in research on senolytic CAR T cells.
The article discusses the potential of senolytic CAR T cells to treat chronic pathologies.
The study was conducted in mice and its results cannot be applied to humans.
In the study, the researchers injected mice with CAR T cells that they genetically modified to seek out and attack senescent cells.
> The protective effect of one treatment seemed to last about a year in the mice (lab mice typically live around two years).
Unlike small molecules, CAR T cells only require that the target antigen is differentially expressed on target cells compared to normal tissues and have the potential to persist and mediate their potent effects for years after single administration.
> The key to slowing ageing is hidden within the white blood cells known as T cells.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(30%)
The article is deceptive in several ways. Firstly, the title claims that the treatment rejuvenates old mice and turns back the clock on some of the damage getting old can wreak. However, this statement is not supported by any evidence presented in the article as there are no results shown to prove that these effects were observed.
The study was conducted in mice and its results, while tantalizing, cannot be applied to humans.
Fallacies
(75%)
The article contains several fallacies. The author uses an appeal to authority by stating that the study was conducted in mice and its results cannot be applied to humans. However, this is not true as animal studies have been used successfully in many cases to test treatments for human diseases. Additionally, the author makes a false dilemma by stating that there are only two options: either slow or reverse aging or suffer from poor health associated with old age. This oversimplifies complex issues and ignores other potential solutions such as lifestyle changes and preventative measures. The article also contains inflammatory rhetoric when it states that the results of the study were
Bias
(75%)
The article is biased towards the idea that this experimental treatment can slow aging and rejuvenate old mice. The author uses phrases like 'remarkable', 'tantalizing pathway for future research' and quotes from researchers saying things like 'If we give it to aged mice, they rejuvenate'. These statements suggest a positive outlook on the results of the study without providing any evidence that this treatment can actually extend lifespan in humans. Additionally, there is no mention of any potential negative effects or limitations of this treatment.
— an obsession that captures the hearts and minds of scientists, billionaires and wellness fanatics alike.
Crucially, the mice seemed to experience no adverse affects from the CAR T cell therapy.
•If we give it to aged mice, they rejuvenate.’ If we give it to young mice, they age slower.
remarkable
tantalizing pathway for future research
Site
Conflicts
Of
Interest (50%)
The article discusses a study conducted in mice that used CAR T cell therapy to slow and potentially reverse the aging process. The author of the article is Claire Cameron.
.
‘Rejuvenates’ old mice.
The protective effect of one treatment of the CAR-T cell therapy seemed to last about a year in the mice (lab mice typically live around two years).
Author
Conflicts
Of
Interest (50%)
The article discusses a study conducted in mice that used CAR T cell therapy to treat aging. The author of the article is Claire Cameron.